---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-239362"
form_type: "8-K"
ticker: "KLRA"
cik: "0002096997"
company_name: "Kailera Therapeutics, Inc."
filed_at: "2026-05-26T20:18:46+00:00"
generated_at: "2026-05-26T20:21:20.754452+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kailera Q1 net loss $78.9M; advances obesity pipeline with Phase 3 start and positive data

## Summary
- Net loss of $78.9M in Q1 2026 vs $18.0M in Q1 2025; R&D expenses rose to $70.9M from $10.1M.
- Cash $581.9M plus IPO proceeds of $718.8M expected to fund operations into mid-2028.
- Initiated global Phase 3 KaiNETIC program for ribupatide injection; data expected 2028.
- Positive Phase 2 oral ribupatide data: mean weight loss up to 12.1% at week 26; Phase 3 trials planned for early 2027.
- Positive Phase 1 data for KAI-4729 tri-agonist: up to 16.0% weight loss at 12 weeks; Phase 1 outside China planned 2026.

## SEC filing metadata
- accession: 0001193125-26-239362
- form_type: 8-K
- ticker: KLRA
- cik: 0002096997
- company_name: Kailera Therapeutics, Inc.
- filed_at: 2026-05-26T20:18:46+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/0001193125-26-239362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2096997/000119312526239362/ck0002096997-20260526.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-239362
- JSON: https://secwatch.observer/filing/0001193125-26-239362.json
- Plain text: https://secwatch.observer/filing/0001193125-26-239362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.